Background: Gout is the most common inflammatory arthritis in adults. It is caused by the chronic deposition of monosodium urate crystals in joints. Hypertension, diabetes mellitus, chronic kidney disease (CKD) and cardiovascular disease are highly prevalent in gout patients.

Nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids or colchicine are the first line therapeutic agents for flares. These drugs can be contraindicated in a large group of gout patients. Off label prescription of IL-1 receptor blockage with anakinra can be an alternative for this complex patients.

Objectives: The main objective of this study is to perform a scoping review about patient characteristics, comorbidity, effectivity and safety profile of patients with gout treated with anakinra.

Methods: A total of 1119 citations were screened. The reviewers performed a two-stage screening by title/abstract and full-text screening. Thirty six articles that finally met selection criteria, were included for data extraction and synthesis. Treatment duration of ≥ 12 weeks was considered chronic.

Results: Four hundred forty three patients were included in the study. 20 patients (4.5%) received chronic treatment and 423 (95.5%) flare treatment. Outcomes from 496 flares were finally analyzed.

The mean age of the patients was 63.6 years and 84% were men. The clinical presentation was polyarticular in 47.9% and tophaceous gout in 66.5%. Some of these patients presented atypical forms of the disease such as spinal gout, autoinflammatory syndromes or sternoclavicular joint arthritis.

Most of the patients presented comorbidities, the most prevalent being arterial hypertension in 127 (70.5%) and chronic kidney disease (≥ 3 stage) in 220 (51.8%). History of transplant in 37 (14.6%) with stem cell, kidney, heart, and liver transplant. More than half of patients had more than one associated comorbidity. Demographic and clinical characteristics of gouty arthritis patients are presented in Table 1. Flare was present in admitted patients in 260 (57.5%). Anakinra was administered in 52 patients with an active infection.

Different treatment regimens were described. Daily administration was used in 98% of the patients. 92.8% of the flares were treated seven days or less, being the three days regimen the most prevalent. In the chronic group the longest treatment reported was 5 years.

Efficacy of treatment with anakinra was evidenced, in flare 426 patients (93%) and chronic 19 patients (91%). Overall, anakinra was well tolerated. In the case of flares, thirty-three (7.9%) adverse effects related to anakinra administration were registered: seven (1.6%) site injection reactions, five (1.1%) reversible hematological alterations and five acute infections (H1N1, herpes zoster, severe cold, pulmonary abscess and nosocomial pyelonephritis). In chronic treated patients, adverse infectious events were more prevalent, seven (32%) infections (*Staphylococcus aureus* tophus (2), *Staphylococcus aureus* lung abscess, erysipela of the leg, *Streptococcus B* urinary tract infection, *Staphylococcus aureus* knee arthritis and tuberculous cervical lymphadenitis).

Conclusion: Anakinra has been shown to be effective and safe in treatment for flares in gout complex or resistant patients. It has been shown in multiples scenarios like active infections, dialysis, transplants, chronic kidney disease, tophi and polyarticular disease refractory to standard treatment. It has also shown its effectiveness as chronic treatment, but there are more concerns about its safety. These findings need to be confirmed with controlled clinical trials for anakinra inclusion in treatment recommendations in special situations of flares in complex or resistant gout patients.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.3455

AB0644

EVALUATION OF MONOCYTE TO HIGH-DENSITY LIPOPROTEIN RATIO AND CAROTID INTIMA MEDIA THICKNESS IN GOUT PATIENTS

C. Kadiyiran¹, A. Kucuk², H. Aydemir², A. U. Uslu³. ¹Necmettin Erbakan University, Radiology department, Konya, Turkey; ²Necmettin Erbakan University, Rheumatology Department, Konya, Turkey; ³Eskisehir Yunus Emre State Hospital, Internal Medicine Department, Eskisehir, Turkey

Background: The aim of this study is to investigate, evaluation of monocyte to high density lipoprotein ratio and carotid intima media thickness in gout patients.

Objectives: Gout disease is an autoinflammatory disease caused by the accumulation of monosodium urate crystals (MSU) in tissues and organs due to hyperuricemia (1). It is a common cause of arthritis due to the changes in lifestyle and eating habits. The effects of the inflammatory process and hyperuricemia in gout are not limited to the joints, but are associated with increased atherosclerosis and cardiovascular disease (1,2) Monocyte to high-density lipoprotein cholesterol ratio (MHR) is a systemic inflammatory marker and has recently been used quite widely for the evaluation of inflammation in cardiovascular disorders (3,4).

Methods: Forty eight patients who were evaluated in the rheumatology clinic with an arthritis attack and diagnosed with Gout, and 48 healthy individuals whose age, gender and body mass index were matched were included in our study. Basic laboratory and biochemical parameters of the period when gout patients were asymptomatic were examined. Carotid intima-media thickness (CIMT), which is a non-invasive procedure due to its widespread use, was used as a marker.

Results: MHR and CIMT values were 18.22 ± 9.01 and 0.76 ± 0.11 mm in patients with gout. In the control group, it was 13.62 ± 4.48 and 0.65 ± 0.13 ($p = 0.002$, $p < 0.0001$, respectively). When evaluated within the study group, it was found that there was a positive correlation between MHR and CIMT ($r = 0.253$, $p = 0.013$), and according to linear regression analysis, there was an independent relationship between MHR and CIMT ($\beta = 0.293$, $p = 0.049$). When assessing Gout patients in the study population, a cutoff value of 13.85 with sensitivity of 66 %, specificity of 53 %, and $p = 0.011$ (area under curve: 0.650, 95% confidence interval 0.540-0.760), was observed according to receiver-operating characteristic curve analysis (Figure 1).

Figure 1. Receiver-operating characteristic curve analysis.

Conclusion: This study showed us that MHR can be an inexpensive and easily accessible marker that can be used in the evaluation of atherosclerotic lesions. We think that studies with larger number of patients are needed on this subject.

REFERENCES:

- [1] Çukurova S, Pamuk ON, Unlu Ercument, Pamuk GE, Cakir NE. Subclinical atherosclerosis in gouty arthritis patients: a comparative study. *Rheumatol Int.* 2012 Jun; 32(6): 1769-73.
- [2] Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. *Circulation* 2007 Aug 21; 116 (8): 894-900.
- [3] McAdams-DeMarco MA, Maynard JW, Coresh J, Baer AN. Anemia and the onset of gout in a population-based cohort of adults: Atherosclerosis Risk in Communities study. *Arthritis Res Ther.* 2012 Aug 20; 14(4): R193.
- [4] Enhos A, Cosansu K, Huyut MA, Turna F, Karacop E, Bakshaliyev N, Nadir A, Ozdemir R, Uluganyan M. Assessment of the Relationship between Monocyte to High-Density Lipoprotein Ratio and Myocardial Bridge. *Arq Bras Cardiol.* 2019 Jan; 112(1):12-17.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.3579

AB0645

CLINICAL CHARACTERISTICS OF GOUT PATIENTS WITH RENAL CYSTS

E. Feng¹, Y. Huang¹, Y. Liu¹, Z. Zhong¹, W. Deng¹, T. W. Li¹. ¹Guangdong Second Provincial General Hospital, Department of Rheumatology and Immunology, Guangzhou Shi, China

Background: Gout is a crystal-related arthropathy caused by monosodium urate deposition, which is a common and treatable form of inflammatory arthritis and becoming more prevalent[1]. A few studies have found that gout patients have an increased prevalence of simple renal cysts[2, 3]. The relationship between gout and renal cysts is still insufficient.

Objectives: Compare the difference between gout with renal cyst and without renal cyst.

Methods: We retrospectively collected data on 200 gout patients. The data includes age, gender, uric acid, creatinine, glomerular filtration rate, 24-hour urine collection, and whether they have kidney stones, renal cysts, coronary heart disease, hypertension, and diabetes. Chi-square and exact Fisher's tests were utilized, while continuous variables were assessed by Student's t-test. A P value of less than 0.05 was considered statistically significant.

Results: Of the 200 gout patients, 56 have kidney cysts(28%). In gout patients who had a renal cyst, were significantly older than patients without renal cysts

(59.14 vs. 46.87, $P = 0.000$), more number of people suffering from coronary heart disease (7 vs. 5, $P = 0.016$). The glomerular filtration rate was lower (58.5 vs. 71.6, $P = 0.000$), with lower urinary creatinine, uric acid, and urinary potassium. **Conclusion:** Gout patients with and without simple renal cysts have significant differences in age, hypertension, cardiovascular disease, GFR, serum creatinine, urine creatinine, and urine potassium.

REFERENCES:

- [1] N. Dalbeth, T.R. Merriman, L.K. Stamp, Gout, *Lancet* 388(10055) (2016) 2039-2052.
- [2] E.M. Hasegawa, R. Fuller, M.C. Chammas, F.M. de Mello, C. Goldenstein-Schainberg, Increased prevalence of simple renal cysts in patients with gout, *Rheumatol Int* 33(2) (2013) 413-6.
- [3] Y. Han, M. Zhang, J. Lu, L. Zhang, J. Han, F. Zhao, H. Chen, Y. Bao, W. Jia, Hyperuricemia and overexcretion of uric acid increase the risk of simple renal cysts in type 2 diabetes, *Sci Rep* 7(1) (2017) 3802.

Table 1. Clinical characteristics of gout patients

	Renal cyst(n=56)	Without Renal cyst(n=144)	P
Disease duration, (month)	98.7(±64.1)	91.2(±67.0)	0.468
Age, (year)	59.14(±14.3)	46.78(±15.9)	0.000
Gender, n(F/M)	7/49	11/133	0.281
Smoking history, n(%)	18(32.1%)	47(32.6%)	0.946
Drinking history, n(%)	10(17.9%)	32(22.2%)	0.496
Hypertension, n(%)	31(55.3%)	49(34.0%)	0.006
Diabetes, n(%)	9(16.1%)	15(10.4%)	0.269
CVDs, n(%)	7(12.5%)	5(3.4%)	0.016
Nephrolithiasis, n(%)	14(25%)	43(29.9%)	0.494
UA, (μmol/L)	494.8(±158.0)	544.3(±121.0)	0.037
Serum creatinine, (μmol/L)	139.4(±57.2)	116.5(±35.45)	0.007
GFR, (ml/L)	58.5(±22.5)	71.6(±22.3)	0.000
FEUA, (%)	7.0(±3.2)	6.0(±3.2)	0.052
Urine creatinine, (μmol/L)	4687.09(±1832.9)	5565.2(±2599.8)	0.008
Urine Uric acid, (μmol/L)	1204.9(±772.0)	1542.1(±1048.5)	0.030
Urine sodium, (mmol)	132.1(±68.7)	131.2(±76.6)	0.939
Urine potassium, (mmol)	25.6(±12.5)	31.8(±14.2)	0.005

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.3702

AB0646

COMPARATIVE ANALYSIS OF ASYMPTOMATIC HYPERURICEMIA AND GOUT - AN IMPACT ON KIDNEY STRUCTURE AND FUNCTION

M. Hristova¹, A. Kundurdzhiev¹, T. Kundurdzhiev², R. Gancheva³. ¹University Hospital St Ivan Rilski, Medical University Sofia, Internal Medicine, Sofia, Bulgaria; ²Faculty of Public Health, Medical University Sofia, Department of Occupational Medicine, Sofia, Bulgaria; ³University Hospital St Ivan Rilski, Medical University Sofia, Rheumatology, Sofia, Bulgaria

Background: The significance of asymptomatic hyperuricemia (AH) continues to be debated. At the population level, asymptomatic hyperuricemia is associated with multiple comorbidities, including hypertension, coronary artery disease, diabetes and chronic kidney disease.¹

Objectives: To investigate the impact of asymptomatic hyperuricemia on renal functional and structural parameters in comparison with symptomatic gout.

Methods: The subjects included in the study were divided into two groups - 46 patients with asymptomatic hyperuricemia and 18 diagnosed with gout according to ACR/EULAR 2015 criteria.² For renal function assessment urine analysis, albuminuria, estimated glomerular filtration rate (eGFR) based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation were used. Diagnostic ultrasound as well as renal biopsy were performed to evaluate structural and histological kidney changes. Statistical analysis was performed using SPSS 22.0 software (SPSS Inc, Chicago, USA).

Results: There were no significant differences between the two groups on serum uric acid levels, albuminuria, and eGFR. However, erythrocyturia ($p=0.047$) and nephrolithiasis ($p<0.001$) prevailed significantly in patients with gout, 66.7% and 61.1% respectively. We did not find any histological differences between the two groups regarding the number of affected glomeruli, tubular atrophy and percentage of interstitial fibrosis based on light microscopy scans.

Conclusion: Our results indicate that patients with AH need renal screening since both AH and gout show similar kidney changes. Further research is needed to elucidate the role of early treatment with xanthine oxidase inhibitor for asymptomatic hyperuricemia as prevention of complications such as erythrocyturia and nephrolithiasis.

REFERENCES:

- [1] Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic? *Curr Opin Rheumatology* 2020; 32(1):71-79 doi: 10.1097/BOR.0000000000000679.
- [2] Neogi T, Jansen TL, Dalbeth N et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheumatology* 2015;67(10):2557-68. doi: 10.1002/art.39254.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.4306

Infection-related rheumatic diseases

AB0647

CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME TRIGGERED BY CONCURRENT VZV AND HSV INFECTION. A CASE REPORT

L. Kakoullis¹, K. Parperis^{2,3}, S. Psarelis⁴, E. Papachristodoulou¹, G. Panos^{5,6}.

¹University of Cyprus Medical School, Department of Medicine, Nicosia, Cyprus; ²University of Cyprus Medical School, Department of Medicine, Division of Rheumatology, Nicosia, Cyprus; ³University of Arizona College of Medicine, Department of Medicine, Division of Rheumatology, Phoenix, Arizona, United States of America; ⁴Nicosia General Hospital, Department of Rheumatology, Nicosia, Cyprus; ⁵University General Hospital of Patras, Department of Internal Medicine, Section of Infectious Diseases, Patras, Greece; ⁶University of Cyprus Medical School, Department of Internal Medicine, Nicosia, Cyprus

Background: Catastrophic antiphospholipid syndrome (CAPS) is a severe autoimmune condition, characterized by multiorgan failure due to thromboses and/or hemorrhage. Concurrent HSV/VZV infection is an exceedingly rare event, occurring mostly in immunocompromised patients. Herein, we report the first case of CAPS triggered by concurrent HSV/VZV infection, manifesting with zosteriform rash and haemorrhages at multiple sites.

Objectives: To describe a case of CAPS provoked by concurrent HSV/VZV infection, manifesting with zosteriform rash and haemorrhages at multiple sites.

Methods: A 36-year-old male, with a history of antiphospholipid syndrome (APS) presented with a 5-day history of epigastric pain, associated with fever, hematuria, rash and swelling in bilateral ears. Past medical history was remarkable for APS, based on 4 episodes of DVT/PE and triple positive antiphospholipid antibodies, on chronic well-maintained warfarin anticoagulation. On examination, a purpuric rash was evident on the right side of the neck as well as on both ears, consistent with a C3 dermatomal distribution (Figure 1). Laboratory studies revealed anemia, thrombocytopenia and acute kidney injury.

Figure 1.